Advanced Filters
noise

seasonal-affective-disorder-sad Clinical Trials

A listing of seasonal-affective-disorder-sad medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6 clinical trials

Aom0319 SAD Study in Healthy Subjects

Only SAD study will be conducted in this project. SAD represents single ascending dose. Multiple ascending dose have been cancelled. This decision has been made at the discretion of the Sponsor.

18 - 55 years of age Both Phase 1

QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects

The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling a total of five ~ six cohorts of healthy participants, a multiple-dose ascending (MAD) phase (Part B) enrolling 3 cohorts of healthy participants, and a food effect study (Part C).

18 - 55 years of age Both Phase 1

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

This is a Phase 1 study to test the safety and drug effects of MDI-2517 when given once in healthy volunteers.

18 - 55 years of age Both Phase 1
S Study Coordinator

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses. RBN-3143 is a PARP-14 inhibitor. PARP14 is over-expressed in tissues with inflammatory diseases. RBN-3143 is a novel, orally administered PARP14 inhibitor that …

18 - 65 years of age Both Phase 1
X Xiaojie Wu

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

This phase 1 study was designed to evaluate the safety and tolerability of SZEY-2108 in single and multiple intravenous infusions, the pharmacokinetic profile of SZEY-2108 after single and multiple intravenous infusions, and the effect of exposure to SZEY-2108 after a single intravenous infusion on QT/QTc interval. Metabolites in each biological …

18 - 45 years of age Both Phase 1
C Cristina Boccabella

Small Airways Disease (SAD) in Severe Asthma as a Novel Endpoint and Distinct Target for Biological Therapy.

Severe asthma is now widely accepted to be a heterogeneous syndrome consisting of multiple phenotypes identified by specific biomarkers and targeted by tailored biological therapies. However, much remains unclear regarding the best approaches to manage these patients, or concerning the pathophysiological mechanisms underlying the disease. Small airway (SA) are defined …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI